Literature DB >> 12709776

Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs.

Bruce M Cohen1, Sara Cherkerzian, Jianyi Ma, Nancy Ye, Carrie Wager, Nicholas Lange.   

Abstract

RATIONALE: Determining brain regions in which neuroleptic drugs of different types produce similar effects, especially where these effects are not shared with drugs lacking antipsychotic efficacy, provides evidence as to how and where the clinical effects of neuroleptic drugs are mediated.
OBJECTIVE: For this study, the pattern of expression of the protein Fos, a marker of cellular activation, was compared after administration of the typical neuroleptic haloperidol, the antipsychotic drug clozapine, and the atypical neuroleptic olanzapine, as well as the sedative drug diphenhydramine and the anxiolytic lorazepam.
METHODS: Animals (Sprague-Dawley rats, three per cohort) received intraperitoneal injections of haloperidol (1 mg/kg), clozapine (20 mg/kg), olanzapine (5 mg/kg), diphenhydramine hydrochloride (1 mg/kg), lorazepam (5 mg/kg) or vehicle (2% lactic acid, 1 ml/kg). Two hours after drug administration, animals were killed. Patterns of activated cells were observed by immunohistochemistry for Fos-like antibodies in regions previously suggested as responding to all antipsychotic drugs, including nucleus accumbens, central amygdala, and central medial thalamus. Cells staining for Fos were counted by semi-automated methods. RESULTS. A very similar pattern and number of Fos positive cells in nucleus accumbens, central amygdala, and central medial thalamus followed administration of each antipsychotic drug. The numbers of apparently activated cells were much greater following antipsychotic drug administration than after vehicle, with differences between each drug and vehicle being highly statistically significant in each region. Lorazepam produced apparent activation of cells of the central amygdala similar in degree and location but not identical in distribution to that of antipsychotic drugs. Diphenhydramine produced no apparent activation of cells in any of the sites tested.
CONCLUSION: Typical and atypical antipsychotic drugs shared a distinctive pattern of robust activation of cells in nucleus accumbens, central medial thalamus, and central amygdala. Antipsychotic drug-induced activation of amygdala was shared by lorazepam, but activation of thalamus and nucleus accumbens was much greater following antipsychotic drugs than following lorazepam. The pattern of activated cells may be relevant to the therapeutic actions of antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709776     DOI: 10.1007/s00213-003-1423-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

Review 1.  Alterations of thalamic activity in schizophrenia and in response to antipsychotic drugs: studies in the legacy of Seymour S. Kety.

Authors:  B M Cohen; D Yurgelun-Todd
Journal:  Neuropsychopharmacology       Date:  2001-09       Impact factor: 7.853

Review 2.  New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata.

Authors:  G F Alheid; L Heimer
Journal:  Neuroscience       Date:  1988-10       Impact factor: 3.590

Review 3.  The involvement of nucleus accumbens dopamine in appetitive and aversive motivation.

Authors:  J D Salamone
Journal:  Behav Brain Res       Date:  1994-04-18       Impact factor: 3.332

4.  Distribution of effects of haloperidol on energy metabolism in the rat brain.

Authors:  J McCulloch; H E Savaki; L Sokoloff
Journal:  Brain Res       Date:  1982-07-08       Impact factor: 3.252

5.  Lower concentration of thalamic n-acetylaspartate in patients with schizophrenia: a replication study.

Authors:  G Ende; D F Braus; S Walter; F A Henn
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

6.  Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.

Authors:  C A Tamminga; G K Thaker; R Buchanan; B Kirkpatrick; L D Alphs; T N Chase; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1992-07

7.  Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder.

Authors:  W Byne; M S Buchsbaum; E Kemether; E A Hazlett; A Shinwari; V Mitropoulou; L J Siever
Journal:  Arch Gen Psychiatry       Date:  2001-02

8.  Magnetic resonance imaging of brain in people at high risk of developing schizophrenia.

Authors:  S M Lawrie; H Whalley; J N Kestelman; S S Abukmeil; M Byrne; A Hodges; J E Rimmington; J J Best; D G Owens; E C Johnstone
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

9.  Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja.

Authors:  G A MacGibbon; P A Lawlor; R Bravo; M Dragunow
Journal:  Brain Res Mol Brain Res       Date:  1994-04

10.  Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine.

Authors:  G S Robertson; H C Fibiger
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

View more
  7 in total

Review 1.  Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?

Authors:  John Lisman
Journal:  Curr Opin Neurobiol       Date:  2011-11-11       Impact factor: 6.627

2.  Individual contribution of metabotropic glutamate receptor (mGlu) 2 and 3 to c-Fos expression pattern evoked by mGlu2/3 antagonism.

Authors:  Alfred Hetzenauer; Corrado Corti; Stefanie Herdy; Mauro Corsi; Francesco Ferraguti; Nicolas Singewald
Journal:  Psychopharmacology (Berl)       Date:  2008-09-24       Impact factor: 4.530

3.  Regulation of neuronal activation by Alpha2A adrenergic receptor agonist.

Authors:  Valentina L Savchenko; John D Boughter
Journal:  Neurotox Res       Date:  2010-12-30       Impact factor: 3.911

Review 4.  Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia.

Authors:  Fulvio A Scorza; Andrea Schmitt; Roberta M Cysneiros; Ricardo M Arida; Esper A Cavalheiro; Wagner F Gattaz
Journal:  Clinics (Sao Paulo)       Date:  2010-05       Impact factor: 2.365

5.  Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei.

Authors:  William Byne; Stella Dracheva; Benjamin Chin; James M Schmeidler; Kenneth L Davis; Vahram Haroutunian
Journal:  Schizophr Res       Date:  2007-10-29       Impact factor: 4.939

6.  Trait anger modulates neural activity in the fronto-parietal attention network.

Authors:  Nelly Alia-Klein; Rebecca N Preston-Campbell; Scott J Moeller; Muhammad A Parvaz; Keren Bachi; Gabriela Gan; Anna Zilverstand; Anna B Konova; Rita Z Goldstein
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

7.  Combined In Silico, Ex Vivo, and In Vivo Assessment of L-17, a Thiadiazine Derivative with Putative Neuro- and Cardioprotective and Antidepressant Effects.

Authors:  Alexey Sarapultsev; Pavel Vassiliev; Daniil Grinchii; Alexander Kiss; Mojmir Mach; Jana Osacka; Alexandra Balloova; Ruslan Paliokha; Andrey Kochetkov; Larisa Sidorova; Petr Sarapultsev; Oleg Chupakhin; Maxim Rantsev; Alexander Spasov; Eliyahu Dremencov
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.